Literature DB >> 1696288

Epithelial markers in pancreatic carcinoma: immunoperoxidase localisation of DD9, CEA, EMA and CAM 5.2.

E Heyderman1, S E Larkin, P J O'Donnell, A M Haines, P J Warren, A Northeast, A G Grant.   

Abstract

Paraffin wax embedded, formalin fixed sections of 22 adenocarcinomas of the exocrine pancreas were stained with four mouse monoclonal antibodies: DD9-E7, an antibody raised against a human pancreatic tumour xenograft; carcino-embryonic antigen (CEA); epithelial membrane antigen (EMA); and cytokeratin (CAM 5.2). An indirect immunoperoxidase technique without enzyme pre-digestion and an affinity-purified sheep anti-mouse peroxidase conjugate were used. All of the tumours were positive for DD9-E7, EMA, and CAM 5.2. Twenty out of 22 were focally positive for CEA and the staining was often weak. As all of these adenocarcinomas were DD9-E7 positive, absence of staining for DD9-E7 in a tumour makes the diagnosis of adenocarcinoma of the exocrine pancreas very unlikely, and this is of value in distinction from endocrine carcinomas with a marked acinar pattern. The weak CEA staining distinguished pancreatic carcinomas from colorectal tumours. Because the distribution of staining for EMA and CAM 5.2 was no different from that previously seen in adenocarcinomas from other sites, these markers are likely to be of limited value in the differential diagnosis of abdominal adenocarcinomas of uncertain origin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1696288      PMCID: PMC502494          DOI: 10.1136/jcp.43.6.448

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  36 in total

1.  Application of the immunoperoxidase method for rapid intraoperative pathological diagnosis of pancreatic cancer.

Authors:  T Ichihara; A Nakao; J Sakamoto; T Nonami; A Harada; T Watanabe; H Takagi; H Nagura
Journal:  J Surg Oncol       Date:  1989-01       Impact factor: 3.454

2.  Survival in 1001 patients with carcinoma of the pancreas.

Authors:  M M Connolly; P J Dawson; F Michelassi; A R Moossa; F Lowenstein
Journal:  Ann Surg       Date:  1987-09       Impact factor: 12.969

3.  Epithelial markers in thyroid carcinoma: an immunoperoxidase study.

Authors:  N W Wilson; H Pambakian; T C Richardson; M R Stokoe; C A Makin; E Heyderman
Journal:  Histopathology       Date:  1986-08       Impact factor: 5.087

4.  Monoclonal antibodies against CEA-related components discriminate between pancreatic duct type carcinomas and nonneoplastic duct lesions as well as nonduct type neoplasias.

Authors:  B Bätge; K Bosslet; H H Sedlacek; H F Kern; G Klöppel
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

5.  Role of plasma carcinoembryonic antigen in diagnosis of gastrointestinal, mammary, and bronchial carcinoma.

Authors:  D J Laurence; U Stevens; R Bettelheim; D Darcy; C Leese; C Turberville; P Alexander; E W Johns; A M Neville
Journal:  Br Med J       Date:  1972-09-09

6.  A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry.

Authors:  A M Haines; S E Larkin; A P Richardson; R W Stirling; E Heyderman
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

7.  Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry.

Authors:  J Cordell; T C Richardson; K A Pulford; A K Ghosh; K C Gatter; E Heyderman; D Y Mason
Journal:  Br J Cancer       Date:  1985-09       Impact factor: 7.640

8.  Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.

Authors:  P Kuusela; C Haglund; P J Roberts; H Jalanko
Journal:  Br J Cancer       Date:  1987-06       Impact factor: 7.640

9.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES.

Authors:  P GOLD; S O FREEDMAN
Journal:  J Exp Med       Date:  1965-03-01       Impact factor: 14.307

10.  A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2.

Authors:  E Heyderman; I Strudley; G Powell; T C Richardson; J L Cordell; D Y Mason
Journal:  Br J Cancer       Date:  1985-09       Impact factor: 7.640

View more
  4 in total

Review 1.  Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?

Authors:  Benjamin A Krantz; Eileen M O'Reilly
Journal:  Clin Cancer Res       Date:  2017-12-21       Impact factor: 12.531

2.  Use of tumour marker immunoreactivity to identify primary site of metastatic cancer.

Authors:  A R Gamble; J A Bell; J E Ronan; D Pearson; I O Ellis
Journal:  BMJ       Date:  1993-01-30

3.  A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.

Authors:  Bence Sipos; Simone Möser; Holger Kalthoff; Virag Török; Matthias Löhr; Günter Klöppel
Journal:  Virchows Arch       Date:  2003-04-12       Impact factor: 4.064

4.  Identification of a novel subpopulation of tumor-initiating cells from gemcitabine-resistant pancreatic ductal adenocarcinoma patients.

Authors:  Kazuya Shimizu; Sachie Chiba; Yuichi Hori
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.